^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ILT-2 inhibitor

    Related drugs:
    Associations

    News

    Trials
    24d
    Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC (clinicaltrials.gov)
    P1, N=76, Recruiting, LG Chem | N=42 --> 76 | Trial completion date: Feb 2027 --> Mar 2028 | Trial primary completion date: Nov 2025 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Tecentriq (atezolizumab)
    1m
    A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. (clinicaltrials.gov)
    P1, N=9, Terminated, Pfizer | Active, not recruiting --> Terminated; Study terminated as part of strategic considerations and not based on safety concerns.
    Trial termination • First-in-human
    |
    sasanlimab (PF-06801591)
    4ms
    Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors (clinicaltrials.gov)
    P2, N=40, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Libtayo (cemiplimab-rwlc)
    4ms
    Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=125, Terminated, Sanofi | N=456 --> 125 | Active, not recruiting --> Terminated; Early discontinuation based on strategic sponsor decision not driven by any safety concerns
    Enrollment change • Trial termination
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed
    8ms
    Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=456, Active, not recruiting, Sanofi | Trial completion date: Feb 2027 --> Jun 2025 | Trial primary completion date: Feb 2027 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed
    9ms
    A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. (clinicaltrials.gov)
    P1, N=5, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=190 --> 5 | Trial completion date: Feb 2030 --> Oct 2025 | Trial primary completion date: Feb 2029 --> Oct 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    sasanlimab (PF-06801591)
    10ms
    Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=456, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed
    1year
    Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial • Combination therapy
    |
    Libtayo (cemiplimab-rwlc)
    1year
    KEYNOTE-F49: A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=140, Recruiting, ImmunOs Therapeutics AG | Trial primary completion date: May 2024 --> May 2025
    Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)
    |
    Keytruda (pembrolizumab) • IOS-1002
    1year
    A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. (clinicaltrials.gov)
    P1, N=190, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    sasanlimab (PF-06801591)
    1year
    A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. (clinicaltrials.gov)
    P1, N=190, Not yet recruiting, Pfizer | Phase classification: P1/2 --> P1
    Phase classification • Metastases
    |
    sasanlimab (PF-06801591)
    1year
    Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (clinicaltrials.gov)
    P1, N=42, Recruiting, LG Chem | Not yet recruiting --> Recruiting
    Enrollment open • Metastases